|1.||Powis, Garth: 2 articles (10/2006 - 01/2004)|
|2.||Kirkpatrick, Lynn: 2 articles (10/2006 - 01/2004)|
|3.||Williams, Ryan: 2 articles (10/2006 - 01/2004)|
|4.||Baker, Amanda F: 2 articles (10/2006 - 01/2004)|
|5.||Ihle, Nathan T: 1 article (10/2006)|
|6.||Winkler, Ashley R: 1 article (10/2006)|
|7.||Stamper, Chelsea: 1 article (01/2004)|
|8.||Gard, Jaime M: 1 article (01/2004)|
|9.||Meuillet, Emmanuelle J: 1 article (01/2004)|
|10.||Ihle, Nathan: 1 article (01/2004)|
04/13/2001 - "OMDPI is currently being investigated as an anti-tumor agent by the National Cancer Institute, NIH. "
10/01/2006 - "Phospho-Akt in mouse hair keratinocytes was inhibited by the Akt inhibitor PX-316 to a lesser degree than in MCF-7 tumor xenografts. "
01/01/2004 - "Gene expression profiling of HT-29 tumor xenografts shows many similarities between the effects of PX-316 and the PtdIns-3-K inhibitor wortmannin, with downregulation of several ribosomal-related genes, while PX-316 uniquely increases the expression of a group of mitochondrial-related genes. "
01/01/2004 - "PX-316 administered intraperitoneally to mice at 150 mg/kg inhibits Akt activation in HT-29 human tumor xenografts up to 78% at 10 h with recovery to 34% at 48 h. "
04/13/2001 - "An ether-containing phosphatidyl inositol(PI) analog, OMDPI, 1-[(1-O-octadecyl-2-O-methyl-sn-glycero)-phospho]-1D-3-deoxy-myo-inositol, is a potent inhibitor of this pathway and may be clinically useful in the treatment of a variety of neoplasms. "
|3.||Colonic Neoplasms (Colon Cancer)
|4.||Breast Neoplasms (Breast Cancer)
|3.||Ethyl Ether (Ether)
|4.||Dihydrotachysterol (AT 10)
|1.||Heterologous Transplantation (Xenotransplantation)